OTCPK:HMTX.F

Stock Analysis Report

Executive Summary

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Hemostemix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HMTX.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

HMTX.F

4.0%

US Biotechs

9.4%

US Market


1 Year Return

-90.2%

HMTX.F

6.1%

US Biotechs

-6.8%

US Market

Return vs Industry: HMTX.F underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: HMTX.F underperformed the US Market which returned -8.1% over the past year.


Shareholder returns

HMTX.FIndustryMarket
7 Day0%4.0%9.4%
30 Day0%2.2%-3.9%
90 Dayn/a-1.5%-16.5%
1 Year-90.2%-90.2%6.9%6.1%-4.8%-6.8%
3 Yearn/a19.2%16.2%23.4%15.2%
5 Yearn/a-5.8%-10.1%41.3%25.7%

Price Volatility Vs. Market

How volatile is Hemostemix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hemostemix undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Hemostemix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Hemostemix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HMTX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Hemostemix regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Hemostemix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemostemix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HMTX.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hemostemix's filings and announcements here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Hemostemix performed over the past 5 years?

-10.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HMTX.F is currently unprofitable.

Growing Profit Margin: HMTX.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HMTX.F is unprofitable, and losses have increased over the past 5 years at a rate of -10.2% per year.

Accelerating Growth: Unable to compare HMTX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HMTX.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: HMTX.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Hemostemix's financial position?


Financial Position Analysis

Short Term Liabilities: HMTX.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HMTX.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HMTX.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HMTX.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HMTX.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HMTX.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.8% each year


Next Steps

Dividend

What is Hemostemix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HMTX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HMTX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HMTX.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HMTX.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HMTX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average board tenure


CEO

Thomas Smeenk (57yo)

0.17

Tenure

Mr. Thomas A. Smeenk, BA, is the founder and serves as President and Director at Hemostemix Inc. since December 2019 and serves as Chief Executive Officer since 2020. He served as Interim Chief Executive O ...


Board Members

NamePositionTenureCompensationOwnership
Thomas Smeenk
President0.17yrno data0.79% CA$51.4k
Peter Lacey
Chairman0.083yrno data8.35% CA$540.6k
David Wood
Independent Director3.25yrsno data0.88% CA$56.8k
Norman C. Wong
Member of Scientific Advisory Board2.33yrsno datano data
Alan Lumsden
Member of Scientific Advisory Boardno datano datano data
Pierre Leimgruber
Member of Scientific Advisory Board0.17yrno datano data
Ronnie Hershman
Director0.17yrno data1.87% CA$121.3k
Kumar Hari
Member of Scientific Advisory Board2.33yrsno datano data
York Hsiang
Member of Scientific Advisory Board0.083yrno datano data

0.3yrs

Average Tenure

63yo

Average Age

Experienced Board: HMTX.F's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HMTX.F insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hemostemix Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hemostemix Inc.
  • Ticker: HMTX.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$9.067m
  • Listing Market Cap: CA$6.476m
  • Shares outstanding: 604.44m
  • Website: https://www.hemostemix.com

Number of Employees


Location

  • Hemostemix Inc.
  • 300 – 5 Avenue SW
  • Suite 2150
  • Calgary
  • Alberta
  • T2P 3C4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HEMTSXV (TSX Venture Exchange)YesCommon SharesCACADDec 2012
HEMTSXV (TSX Venture Exchange)YesCommon SharesCACADDec 2012
HMTX.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 2012

Biography

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, an autologous cell therapy for the treatment of critical limb ischemia, which is in Phase II clinical trial in Canada and the United States. It is also developing various types of cells products, such as synergetic cell populations, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 03:18
End of Day Share Price2020/03/09 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.